FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W11164669> ?p ?o ?g. }

• W11164669 endingPage "831" @default.
• W11164669 startingPage "825" @default.
• W11164669 abstract "Seventy-six prepubertal children receiving autologous or allogeneic bone marrow transplantation (BMT) were enrolled in a prospective study on the impact of different pretransplant preparative regimens on growth. Patients were divided into three groups: group I, consisting of 37 children who had received total body irradiation (TBI) and cytotoxic drugs as preparative regimen; group II, including 17 children receiving prophylactic cranial irradiation before being conditioned with TBI and cytotoxic drugs; and group III, composed of 22 patients transplanted after a busulfan (BU)-containing myeloablative therapy. All patients have a minimum follow-up of 2 years, whereas 48 and 34 patients have been studied until 3 and 4 years after transplant, respectively. Height and growth rate were expressed as standard deviation score (SDS). Growth hormone (GH) secretion in response to pharmacologic stimuli was evaluated after documented growth failure. Patients with GH deficiency were treated with recombinant human GH, and response to therapy was evaluated. The main impairment of growth rate in patients belonging to group II was observed in the first year after TBI (growth rate SDS changing from -0.12 +/- 0.23 to -1.23 +/- 0.25, P < .005), with only a slight loss in the following years, whereas in group I children growth failure occurred in the third year after TBI (-1.36 +/- 0.28 SDS in comparison to a pre-BMT SDS of 0.10 +/- 0.15, P < .005). Therefore, growth velocity between these two groups differed significantly in the first 2 years (P < .01) but subsequently equalized. On the contrary, all BU-treated children but 2 grew normally. GH deficiency was shown in the vast majority of children with growth impairment. Twenty-three children treated with recombinant human GH are evaluable; a successful response was observed in all but 1, with the mean growth rate increasing from -2.29 +/- 0.27 before treatment to 0.86 +/- 0.38 and to 1.66 +/- 0.56 SDS at 1 and 2 years after treatment, respectively (P < .001). In conclusion, growth rate impairment was common in patients receiving TBI, with the speed of onset of both decreased growth velocity and GH deficiency depending mainly on the total dose of radiation. On the contrary, patients receiving BU did not experience significant problems in terms of growth velocity. The timely start of appropriate hormonal replacement therapy may ameliorate the final growth of children undergoing BMT." @default.
• W11164669 created "2016-06-24" @default.
• W11164669 creator A5022712318 @default.
• W11164669 creator A5030187982 @default.
• W11164669 creator A5031685879 @default.
• W11164669 creator A5038061948 @default.
• W11164669 creator A5050682361 @default.
• W11164669 creator A5061275872 @default.
• W11164669 creator A5064645546 @default.
• W11164669 creator A5066721377 @default.
• W11164669 creator A5067276736 @default.
• W11164669 creator A5091370811 @default.
• W11164669 date "1995-07-15" @default.
• W11164669 modified "2023-09-29" @default.
• W11164669 title "Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone" @default.
• W11164669 cites W1489688420 @default.
• W11164669 cites W1903864496 @default.
• W11164669 cites W1973255379 @default.
• W11164669 cites W1976730498 @default.
• W11164669 cites W1983452339 @default.
• W11164669 cites W1989831107 @default.
• W11164669 cites W1992559232 @default.
• W11164669 cites W1994506803 @default.
• W11164669 cites W2000015158 @default.
• W11164669 cites W2005838483 @default.
• W11164669 cites W2023463391 @default.
• W11164669 cites W2023547547 @default.
• W11164669 cites W2027129545 @default.
• W11164669 cites W2029671510 @default.
• W11164669 cites W2035558487 @default.
• W11164669 cites W2047968973 @default.
• W11164669 cites W2056097741 @default.
• W11164669 cites W2067141105 @default.
• W11164669 cites W2079865696 @default.
• W11164669 cites W2083592308 @default.
• W11164669 cites W2085178541 @default.
• W11164669 cites W2089476572 @default.
• W11164669 cites W2129224839 @default.
• W11164669 cites W2227246587 @default.
• W11164669 cites W2329522359 @default.
• W11164669 cites W2408431432 @default.
• W11164669 cites W2408802436 @default.
• W11164669 cites W2416876555 @default.
• W11164669 cites W2424727642 @default.
• W11164669 cites W69097689 @default.
• W11164669 cites W2521734156 @default.
• W11164669 doi "https://doi.org/10.1182/blood.v86.2.825.bloodjournal862825" @default.
• W11164669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7606014" @default.
• W11164669 hasPublicationYear "1995" @default.
• W11164669 type Work @default.
• W11164669 sameAs 11164669 @default.
• W11164669 citedByCount "114" @default.
• W11164669 countsByYear W111646692012 @default.
• W11164669 countsByYear W111646692013 @default.
• W11164669 countsByYear W111646692014 @default.
• W11164669 countsByYear W111646692015 @default.
• W11164669 countsByYear W111646692016 @default.
• W11164669 countsByYear W111646692017 @default.
• W11164669 countsByYear W111646692018 @default.
• W11164669 countsByYear W111646692019 @default.
• W11164669 countsByYear W111646692021 @default.
• W11164669 countsByYear W111646692022 @default.
• W11164669 crossrefType "journal-article" @default.
• W11164669 hasAuthorship W11164669A5022712318 @default.
• W11164669 hasAuthorship W11164669A5030187982 @default.
• W11164669 hasAuthorship W11164669A5031685879 @default.
• W11164669 hasAuthorship W11164669A5038061948 @default.
• W11164669 hasAuthorship W11164669A5050682361 @default.
• W11164669 hasAuthorship W11164669A5061275872 @default.
• W11164669 hasAuthorship W11164669A5064645546 @default.
• W11164669 hasAuthorship W11164669A5066721377 @default.
• W11164669 hasAuthorship W11164669A5067276736 @default.
• W11164669 hasAuthorship W11164669A5091370811 @default.
• W11164669 hasBestOaLocation W111646691 @default.
• W11164669 hasConcept C126322002 @default.
• W11164669 hasConcept C141071460 @default.
• W11164669 hasConcept C2776694085 @default.
• W11164669 hasConcept C2776755627 @default.
• W11164669 hasConcept C2777408962 @default.
• W11164669 hasConcept C2778880498 @default.
• W11164669 hasConcept C2779952775 @default.
• W11164669 hasConcept C2780611847 @default.
• W11164669 hasConcept C2781413609 @default.
• W11164669 hasConcept C2911091166 @default.
• W11164669 hasConcept C2984496839 @default.
• W11164669 hasConcept C71315377 @default.
• W11164669 hasConcept C71924100 @default.
• W11164669 hasConcept C90924648 @default.
• W11164669 hasConceptScore W11164669C126322002 @default.
• W11164669 hasConceptScore W11164669C141071460 @default.
• W11164669 hasConceptScore W11164669C2776694085 @default.
• W11164669 hasConceptScore W11164669C2776755627 @default.
• W11164669 hasConceptScore W11164669C2777408962 @default.
• W11164669 hasConceptScore W11164669C2778880498 @default.
• W11164669 hasConceptScore W11164669C2779952775 @default.
• W11164669 hasConceptScore W11164669C2780611847 @default.
• W11164669 hasConceptScore W11164669C2781413609 @default.
• W11164669 hasConceptScore W11164669C2911091166 @default.

• next